Outcome and Impact of Specific Treatment in European Research on Melanoma


Cost-shared RTD project

Coordinated by D. Schadendorf, Heidelberg

QLG1-CT2002-00668 (2002-2005)


Melanoma is a refractory disease, for which treatment outcome is currently still very poor. Parameters predicting treatment success are underdeveloped. The prime objective of OISTER is therefore to analyse the patient parameters which may be predictive for treatment response. This will be done by systematically collecting tumour samples from melanoma patients in all clinical stages and over the clinical course of the patient´s disease. Permanent cell lines will be established which will be made available to the partners for analysis as well as to ESTDAB. which collects, characterises and distributes melanoma lines to investigators primarily with a tumour immunological focus.

OISTER is divided into three basic components,

  1. a component dealing with the Clinical Database and Registry, and associated structures;
  2. a component dealing with characterisation of tumour cells and cell lines;
  3. a component directed to tumour antigen discovery and immunological characterisation of tumour cells and lines.

The objective of this proposal is to connect to centres to build a supra-national network of research infrastructure to improve treatment and outcome of cancer therapy.